168 related articles for article (PubMed ID: 23984250)
1. Ingenol mebutate: A novel topical drug for actinic keratosis.
Aditya S; Gupta S
Indian Dermatol Online J; 2013 Jul; 4(3):246-9. PubMed ID: 23984250
[TBL] [Abstract][Full Text] [Related]
2. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
4. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
5. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
6. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
7. Ingenol mebutate treatment in actinic keratosis - clinical effectiveness and potential side effects.
Lesiak A; Maćkowska A; Bednarski IA; Kolano P; Olejniczak-Staruch I; Woźniacka A; Sieniawska J; Narbutt J
Postepy Dermatol Alergol; 2019 Aug; 36(4):468-471. PubMed ID: 31616223
[TBL] [Abstract][Full Text] [Related]
8. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series.
Bobyr I; Campanati A; Consales V; Giuliodori K; Scalise A; Offidani A
Springerplus; 2016; 5():627. PubMed ID: 27330893
[TBL] [Abstract][Full Text] [Related]
10. Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases.
Longo C; Borsari S; Benati E; Moscarella E; Alfano R; Argenziano G
Dermatol Ther (Heidelb); 2016 Mar; 6(1):81-7. PubMed ID: 26847171
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate: potential for further development of cancer immunotherapy.
Doan HQ; Gulati N; Levis WR
J Drugs Dermatol; 2012 Oct; 11(10):1156-7. PubMed ID: 23134979
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.
Skroza N; Bernardini N; Proietti I; Potenza C
Ther Clin Risk Manag; 2018; 14():1879-1885. PubMed ID: 30323610
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
15. Ingenol mebutate: a new option for actinic keratosis treatment.
Gras J
Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
[TBL] [Abstract][Full Text] [Related]
16. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
17. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
19. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
20. Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis.
Righi V; Tarentini E; Mucci A; Reggiani C; Rossi MC; Ferrari F; Casari A; Magnoni C
Sci Rep; 2019 Aug; 9(1):11515. PubMed ID: 31395965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
